BridgeBio Oncology Therapeutics (BBOT) Interest Income - Net (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Interest Income - Net of -$12.0 million for Q1 2026, up 68.8% sequentially from -$38.3 million in Q4 2025, and down 761.36% YoY from $1.8 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Interest Income - Net (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Interest Income - Net for 3 years, with the latest figure at -$12.0 million in Q1 2026.
- Quarterly Interest Income - Net fell 761.36% year-over-year to -$12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$80.9 million (changed N/A YoY) and the FY2025 annual result came in at -$75.8 million, down 95.45% from the prior year.
- Interest Income - Net climbed to -$12.0 million in Q1 2026 per BBOT's latest filing, from -$38.3 million in the prior quarter.
- Over five years, Interest Income - Net peaked at $2.5 million in Q3 2024 and troughed at -$43.0 million in Q4 2024.
- A 3-year average of -$20.2 million and a median of -$22.2 million in 2025 frame the typical range for Interest Income - Net.
- The widest YoY moves for Interest Income - Net: up 10.92% in 2025, down 1410.03% in 2025.
- Over 3 years, Interest Income - Net stood at -$43.0 million in 2024, then gained by 10.92% to -$38.3 million in 2025, then jumped by 68.8% to -$12.0 million in 2026.
- According to Business Quant data, Interest Income - Net over the past three periods registered -$12.0 million, -$38.3 million, and -$32.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Net (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -7.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.07 Mn |
| Mar 31, 2026 | -11.96 Mn |
| Dec 31, 2025 | -38.35 Mn |
| Sep 30, 2025 | -32.40 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | -43.05 Mn |
| Sep 30, 2024 | 2.47 Mn |